FDA Advisory Panel Approves Wider Peptide Use, Sparking Fears of Prescription Surge

The FDA advisory committee voted to broaden the use of peptide drugs. The decision focuses on lightly regulated compounding pharmacies. The FDA advisory committee voted to broaden the use of peptide drugs. The decision focuses on lightly regulated compounding pharmacies.

These pharmacies have grown into a multibillion‑dollar industry. Panel members voiced worries about a rapid increase in prescriptions. Critics fear the move could trigger a prescribing boom. The vote reflects ongoing pressure to expand treatment options. Regulators may

need to monitor prescribing patterns closely. Stakeholders will watch for any impact on drug safety and costs.